AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11216954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 9688064 — intervention group
Group type: EXPERIMENTAL
Intervention: New 50 mg tablet formulation
Number of subjects: 42
Study 9688064 — intervention group
Group type: COMPARATOR
Intervention: Old 50 mg tablet formulation
Number of subjects: 42
Study 9688064 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension containing 50 mg/ml of primidone
Number of subjects: 42
Study 9688064 — intervention group
Group type: EXPERIMENTAL
Intervention: New 250 mg tablet formulation
Number of subjects: 42
Study 9688064 — intervention group
Group type: COMPARATOR
Intervention: Old 250 mg tablet formulation (two lots)
Number of subjects: 42
Study 9688064 — intervention group
Group type: COMPARATOR
Intervention: 250 mg tablet from a second manufacturer
Number of subjects: 42
Study 8081096 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MR) before surgery
Number of subjects: 15
Study 8081096 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative neuropsychological assessment
Number of subjects: 15
Study 8081096 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MR) one week after surgery
Number of subjects: 15
Study 2510223 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.03 mg/kg i.v.
Number of subjects: 10
Study 2510223 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml 0.9% NaCl)
Number of subjects: 10
Study 355026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 375 mg/day
Number of subjects: 134
Study 355026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 750 mg/day
Number of subjects: 134
Study 355026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 1,500 mg/day
Number of subjects: 134
Study 355026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 3,000 mg/day
Number of subjects: 134
Study 355026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 1,500 mg/day or 17‐24 mg/kg body weight
Number of subjects: 134
Study 355026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 31944270 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of methotrexate, once weekly for 6 sittings.
Number of subjects: 62
Study 31944270 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment, twice daily for 6 weeks.
Number of subjects: 62
Study 31944270 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of methotrexate
Number of subjects: 62
Study 31944270 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 62
Study 31240472 — intervention group
Group type: EXPERIMENTAL
Intervention: Plitidepsin 5 mg/m2 on D1 and D15 plus Dexamethasone 40 mg on D1, D8, D15, and D22 (arm A)
Number of subjects: 255
Study 31240472 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 40 mg on D1, D8, D15, and D22 (arm B)
Number of subjects: 255
Study 31240472 — intervention group
Group type: EXPERIMENTAL
Intervention: Plitidepsin plus Dexamethasone (arm A)
Number of subjects: 255
Study 31240472 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone (arm B)
Number of subjects: 255
Study 27495814 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 40
Study 26228390 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth program (MASTERY©) using a mobile application (Breathe-easy©) and a Bluetooth-enabled device (COPD-6®) for self-monitoring of lung function (FEV1, FEV6) twice daily, recording asthma symptoms and medication usage weekly, and a written asthma action plan (WAAP)
Number of subjects: 0
Study 26228390 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth program (MASTERY©)
Number of subjects: 0
Study 26228390 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 23440337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention (case management and youth leadership programs)
Number of subjects: 236
Study 23440337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 236
Study 23440337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study 22176722 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention based on a pedometer (12-week tailored program encouraging increased walking)
Number of subjects: 66
Study 22176722 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention based on a pedometer
Number of subjects: 66
Study 22176722 — intervention group
Group type: COMPARATOR
Intervention: Routine postpartum care (control group)
Number of subjects: 66
Study 17693902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET 175 microg/275 mug
Number of subjects: 90
Study 17693902 — intervention group
Group type: COMPARATOR
Intervention: Oral E2/NET acetate 1 mg/0.5 mg
Number of subjects: 90
Study 17693902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 17297830 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.45 mg x kg(‐1))
Number of subjects: 50
Study 17297830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine plus Propofol (0.45 mg x kg(‐1) of propofol plus 0.25 mg x kg(‐1) of ketamine)
Number of subjects: 50
Study 12941060 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Sleep Onset (NSO)
Number of subjects: 30
Study 12941060 — intervention group
Group type: COMPARATOR
Intervention: Delayed Sleep Onset (DSO)
Number of subjects: 30
Study 10625080 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.20‐0.25 mg/kg, 12 hourly)
Number of subjects: 33
Study 10625080 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (5‐10 mg/kg, 24 hourly)
Number of subjects: 33
Study 10625080 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (after 24-h dose)
Number of subjects: 33
Study 10625080 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (after 48-h dose of saline)
Number of subjects: 33
Study 10625080 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (after 24-h and 48-h doses)
Number of subjects: 33
Study 10625080 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 33
Study 10625080 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 33
Study 9199606 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSA
Number of subjects: 12
Study 9199606 — intervention group
Group type: COMPARATOR
Intervention: Controls (not known to have OSA)
Number of subjects: 12
Study 1591054 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane 62.5 mg
Number of subjects: 43
Study 1591054 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane 125 mg
Number of subjects: 43
Study 1591054 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane 250 mg
Number of subjects: 43
Study 1591054 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane 500 mg
Number of subjects: 43
Study 2580177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 15 mg three times a day
Number of subjects: 255
Study 2580177 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times a day
Number of subjects: 255
Study 2580177 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hydrochlorothiazide and captopril
Number of subjects: 255
Study 30382485 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin + cytarabine + daunorubicin
Number of subjects: 0
Study 30382485 — intervention group
Group type: COMPARATOR
Intervention: Placebo + cytarabine + daunorubicin
Number of subjects: 0
Study 29879277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Valproic Acid (VPA) 500 mg to 1000 mg daily for 12 months
Number of subjects: 90
Study 29879277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26927908 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 345
Study 25015756 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-based topical hemostatic matrix
Number of subjects: 108
Study 25015756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 22645174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (COLD)
Number of subjects: 14
Study 22645174 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast water therapy (CWT)
Number of subjects: 14
Study 22645174 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 14
Study 20452799 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardian RT (real-time glucose-sensor system)
Number of subjects: 10
Study 20452799 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 10
Study 18582257 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (n = 92)
Number of subjects: 180
Study 18582257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 88)
Number of subjects: 180
Study 15200538 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plaster (PAS) applied at the Korean hand acupuncture point (K-A20)
Number of subjects: 150
Study 15200538 — intervention group
Group type: COMPARATOR
Intervention: Sham control (placebo tape at non-acupoints)
Number of subjects: 150
Study 15200538 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (placebo tape at non-acupoints)
Number of subjects: 150
Study 12390621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 95
Study 9422557 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA Class I
Number of subjects: 712
Study 9422557 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA Class III
Number of subjects: 712
Study 9422557 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA Class IV
Number of subjects: 712
Study 9422557 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA Class V
Number of subjects: 712
Study 9422557 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA Class II
Number of subjects: 712
Study 9422557 — intervention group
Group type: COMPARATOR
Intervention: Cox model
Number of subjects: 712
Study 9422557 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA classes
Number of subjects: 712
Study 7861597 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.25 mg given initially, followed by another 0.25 mg 2 hours later)
Number of subjects: 54
Study 7861597 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of flumazenil (0.25 mg in 250 ml of lactated Ringer's solution for 2 hours)
Number of subjects: 54
Study 2618844 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin cues
Number of subjects: 35
Study 2618844 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ratings after exposure to drug stimuli
Number of subjects: 35
Study 2618844 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving without withdrawal sickness
Number of subjects: 35
Study 983629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin
Number of subjects: 107
Study 983629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 107
Study 983629 — intervention group
Group type: COMPARATOR
Intervention: Combined ampicillin and cloxacillin
Number of subjects: 107
Study 30967236 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation fractionation schedules
Number of subjects: 0
Study 30967236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason grade group
Number of subjects: 0
Study 29243165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (INT): Counseling/group discussions coupled with supervised exercise tapered to unsupervised exercise
Number of subjects: 27
Study 29243165 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 27
Study 29243165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (INT)
Number of subjects: 27
Study 26342932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically procured ATOS
Number of subjects: 50
Study 26342932 — intervention group
Group type: COMPARATOR
Intervention: Transcranially procured ATOS
Number of subjects: 50
Study 24628972 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 472
Study 24628972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 472
Study 22150299 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Automatic Threshold (LVAT) algorithm
Number of subjects: 70
Study 21313894 — intervention group
Group type: EXPERIMENTAL
Intervention: M 1.0 (lidocaine 5% and midazolam 1 mg)
Number of subjects: 45
Study 21313894 — intervention group
Group type: EXPERIMENTAL
Intervention: M 0.5 (lidocaine 5% and midazolam 0.5 mg)
Number of subjects: 45
Study 21313894 — intervention group
Group type: COMPARATOR
Intervention: Control (lidocaine 5% plus normal saline)
Number of subjects: 45
Study 17635430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone with dolasetron
Number of subjects: 242
Study 17635430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone with haloperidol
Number of subjects: 242
Study 17635430 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron alone
Number of subjects: 242
Study 17635430 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 242
Study 16298809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand Injury Severity Score (HISS)
Number of subjects: 0
Study 16298809 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-score (Disabilities of the Arm, Shoulder and Hand)
Number of subjects: 0
Study 16298809 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 (Short Form Health Survey)
Number of subjects: 0
Study 16298809 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs of care during an emergency
Number of subjects: 0
Study 16298809 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor injuries
Number of subjects: 0
Study 11852291 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 7
Study 11852291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10355240 — intervention group
Group type: EXPERIMENTAL
Intervention: Full attention during encoding
Number of subjects: 0
Study 10355240 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention during encoding
Number of subjects: 0
Study 10355240 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect test instructions
Number of subjects: 0
Study 7577198 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole abdominal radiotherapy
Number of subjects: 0
Study 7577198 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy with doxorubicin and cisplatin
Number of subjects: 0
Study 2012823 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training for facial relaxation
Number of subjects: 29
Study 2012823 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback training for facial tension stability
Number of subjects: 29
Study 6459839 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (5 g po as a single dose)
Number of subjects: 8
Study 6459839 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan combined with nicotinamide (a tryptophan pyrrolase inhibitor) administered for 1-3 weeks
Number of subjects: 8
Study 6459839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31679857 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to green space
Number of subjects: 2354
Study 31679857 — intervention group
Group type: COMPARATOR
Intervention: Surrounding greenness (measured by NDVI)
Number of subjects: 2354
Study 30640156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task balance training (12 weeks, 3 times/week)
Number of subjects: 95
Study 30640156 — intervention group
Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 95
Study 30640156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task gait
Number of subjects: 95
Study 29417771 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional nail plate system (group A)
Number of subjects: 45
Study 29417771 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-profile device (group B)
Number of subjects: 45
Study 25326008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 7 µg/kg/min (Group D)
Number of subjects: 150
Study 25326008 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 1 µg/kg/min (Group M1)
Number of subjects: 150
Study 25326008 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 2 µg/kg/min (Group M2)
Number of subjects: 150
Study 25326008 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 3 µg/kg/min (Group M3)
Number of subjects: 150
Study 25326008 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving saline (Group C)
Number of subjects: 150
Study 22753544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent blue light (three 30 min pulses over 2 h) once a day for 3 days of free-running
Number of subjects: 0
Study 22753544 — intervention group
Group type: COMPARATOR
Intervention: Dim room light (control)
Number of subjects: 0
Study 19458624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 654
Study 19458624 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 654
Study 19458624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 654
Study 19458624 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 654
Study 17102802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (Casodex) 150 mg plus standard care
Number of subjects: 0
Study 17102802 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 15831604 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 15831604 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary preventive treatments
Number of subjects: 0
Study 14601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma LEP levels in AN patients
Number of subjects: 55
Study 14601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neuropeptide Y (NPY), beta‐endorphin (B‐EP), and galanin (GAL) levels in AN
Number of subjects: 55
Study 14601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum/plasma levels of insulin (I), insulin‐like growth hormone‐1 (IGF‐1), luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2), and free triiodothyronine (fT3) in AN
Number of subjects: 55
Study 14601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (F) levels in AN
Number of subjects: 55
Study 14601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of LEP levels with IRI, IGF‐1, free thyroxine (fT4), and FSH levels in AN
Number of subjects: 55
Study 14601488 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality traits in patients with AN
Number of subjects: 55
Study 10457578 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential therapy
Number of subjects: 152
Study 10457578 — intervention group
Group type: COMPARATOR
Intervention: Motorized lumbar traction and massage
Number of subjects: 152
Study 7576673 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming for one hour before induction of anesthesia
Number of subjects: 16
Study 7576673 — intervention group
Group type: COMPARATOR
Intervention: Wool blanket during a similar preinduction period
Number of subjects: 16
Study 1971630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine antisepsis
Number of subjects: 0
Study 1971630 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 1971630 — intervention group
Group type: COMPARATOR
Intervention: Soap
Number of subjects: 0
Study 6784917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diamminedichloroplatinum (DDP) alone
Number of subjects: 0
Study 6784917 — intervention group
Group type: EXPERIMENTAL
Intervention: ThioTEPA and methotrexate (MTX)
Number of subjects: 0
Study 6784917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diamminedichloroplatinum (DDP) and Adriamycin (ADM)
Number of subjects: 0
Study 6784917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diamminedichloroplatinum (DDP) regimens
Number of subjects: 0
Study 6784917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-diamminedichloroplatinum (DDP) or DDP-ADM
Number of subjects: 0
Study 31488372 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents
Number of subjects: 1300
Study 31488372 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents
Number of subjects: 1300
Study 27939204 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (8 μg/kg 8 hourly)
Number of subjects: 42
Study 27939204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 42
Study 26559501 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone concentrations (total and bioavailable) measured at follow-up years 10 and 17.
Number of subjects: 0
Study 23602210 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills intervention (booklet mailed prior to the consultation)
Number of subjects: 65
Study 23602210 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 17264863 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary management of bone complications
Number of subjects: 0
Study 17264863 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 0
Study 15508051 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant interactions with multiples
Number of subjects: 77
Study 15508051 — intervention group
Group type: COMPARATOR
Intervention: Mother-infant interactions with singletons
Number of subjects: 77
Study 10714911 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of estradiol valerate plus 200 mg of enanthate of dihydroandrosterone im monthly (Group A)
Number of subjects: 120
Study 10714911 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/day of transdermal 17-b-estradiol continuously (Group E)
Number of subjects: 120
Study 10714911 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of tibolone every day (Group T)
Number of subjects: 120